- CELYSTRA Pharma announced that Québec has become the first Canadian province to provide public reimbursement for Tryngolza (olezarsen), the first Health Canada-approved treatment for familial chylomicronemia syndrome (FCS). The therapy is now listed on the RAMQ formulary for eligible patients.
- FCS is a rare genetic disorder marked by extremely high triglyceride levels and recurrent, potentially life-threatening pancreatitis. The disease is more common among French Canadians, particularly in eastern Québec, and previously had no disease-specific treatment beyond a strict low-fat diet.
- Tryngolza, licensed by CELYSTRA Pharma from Ionis Pharmaceuticals, lowers triglyceride levels by targeting apolipoprotein C-III (apoC-III), offering the first approved therapy specifically designed to treat FCS.
- Clinicians and patient groups welcomed the reimbursement decision as a major milestone for rare disease care. CELYSTRA said it is now working with other Canadian provinces to expand public access to Tryngolza for eligible patients nationwide.
Takeaways:
The decision is especially meaningful for CELYSTRA because Québec is a high-prevalence region for FCS among French Canadians, so public coverage can quickly translate into concentrated adoption, validate the company’s licensing-and-access model, and create leverage as it negotiates with other provinces. The broader implication is that province-by-province reimbursement could establish a national pathway for ultra-rare lipid disorders in Canada, improving diagnosis and treatment uptake while supporting Ionis/CELYSTRA’s first-mover position in a disease area with little prior commercial competition.
Source: CA Newswire
